Wellbeing Digital Sciences Inc. - KONEF STOCK NEWS

KetamineOne Capital Limited has announced a one-year exclusive agreement with Victoria Wellness to provide ketamine therapy. The partnership aims to assist clients in treating anxiety, depression, and PTSD through a six-week program named KITE. This program combines ketamine treatment with psychotherapy, enhancing recovery. The first clients are anticipated to begin treatment soon. The company also reported the start of data collection for a PTSD study and completed the rebranding of IRP Health. This agreement aligns with Ketamine One's strategy to expand its network of mental health clinics.

Ketamine One Capital Limited (OTCQB: KONEF) announced its up-listing from the OTC Pink Sheet to the OTCQB Venture Market as of January 12, 2022. This move, alongside the receipt of DTC Eligibility, enhances access for US investors to purchase its shares. The OTCQB is recognized for providing transparent trading options for developmental companies. The company aims to consolidate medical clinics to establish itself as a leader in mental health treatments across North America, supported by its wholly-owned research division.

KetamineOne Capital Limited (KONEF) is pleased to announce its participation as the first founding sponsor of the Psychedelic Science 2023 event, set for June 19-25 in Denver, Colorado. This gathering, organized by MAPS and Momentum Events, is expected to attract around 10,000 attendees and features various panels and workshops on psychedelics. Additionally, the company has granted stock options, restricted share units, and performance warrants to its directors and consultants, with specific vesting schedules and exercise prices detailed.

KetamineOne Capital Limited has announced the appointments of Corey Hilmas and Brigadier General (Ret.) Loree K. Sutton to its Medical Advisory Board to enhance its mental health platform development. Dr. Hilmas, a regulatory expert with FDA experience, brings significant scientific and medical expertise, while Dr. Sutton, a decorated military psychiatrist, adds leadership experience in veterans' mental health. The company also granted stock options totaling 100,000 shares at $0.30 each, with half vesting in six months.

KetamineOne Capital Limited (OTC: KONEF) announced the results of its annual general and special meeting held on December 17, 2021. Shareholders representing 15.69% of total shares voted to set the board of directors at four members, with all nominees elected to serve for the upcoming year. Key actions included the reappointment of auditors, approval of a restricted share unit plan, and authorization of previous grants of restricted share units, all receiving over 98% approval. The company aims to consolidate medical clinics and lead in mental health treatments across North America.

KetamineOne Capital Limited (KONEF) reported revenues of $1,989,752 for the quarter ended October 31, 2021, a significant increase compared to $0 in the same period last year. Gross profit stood at $594,411, while the net loss widened to $9,225,769 due to share-based payments and expenses. Total assets decreased by 13% to $19,079,056. The company is focused on expanding its presence in mental health, having opened new veteran-focused clinics and secured strategic partnerships in telehealth and research. Management remains optimistic about growth and future financial performance.

KetamineOne Capital Limited (KONEF), based in Vancouver, has had its management cease trade order lifted by the British Columbia Securities Commission, effective immediately. This follows the company's filing of audited annual financial statements for the fiscal year ending July 31, 2021, on December 13, 2021. KetamineOne aims to become a leader in mental health treatments across North America by consolidating medical clinics. Their subsidiary, KGK Science Inc., focuses on clinical research in pharmaceuticals and psychedelic medicine.

KetamineOne Capital Limited announces the appointment of Joe Ramelli as the new Chief Financial Officer (CFO) effective December 14, 2021. This transition follows the amicable departure of former CFO Peter Nguyen, who resigns from the Company’s Board of Directors. Ramelli brings nearly 30 years of experience in public markets and financial services, noted for successfully raising significant capital in past roles. Ketamine One plans to submit a registration statement for a potential USD 20 million IPO, marking a significant milestone in its growth strategy focused on mental health treatments.

KetamineOne Capital Limited (KONEF) announced audited financial results for the fiscal year ending July 31, 2021. The Company reported revenue of $1,131,171, with a gross profit of $793,166. However, it recorded a significant net loss of $31,914,151, primarily due to non-cash expenses. Total assets surged by 346% to $21,921,195, driven by the acquisition of KGK Science Inc. Management emphasized ongoing growth and plans for more partnerships in the mental health sector.